Last updated: April 6, 2024
Sponsor: Tarsus Pharmaceuticals, Inc.
Overall Status: Active - Not Recruiting
Phase
2
Condition
Dry Eyes
Dry Eye Disease
Blepharitis
Treatment
Vehicle of TP-03
Exploratory Vehicle
Clinical Study ID
NCT06054217
TRS-021
Ages > 18 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Key Inclusion Criteria:
- Be willing to sign the informed consent and deemed capable of complying with therequirements of the study protocol
- Meets all of the following criteria in at least one eye: have more than 10 lashes withcollarettes present on the upper lid; have the presence of one or more mites with lashepilation of the upper and lower lids; have evidence of meibomian gland dysfunction;have at least mild erythema of the lower lid; have a tear breakup time of less than 10seconds; and have intact partial to full meibomian glands in at least 33% of the totalmeibomian gland area of the lower lid
Exclusion
Key Exclusion Criteria:
- Have used lid hygiene products within 7 days of Day 1 or unwilling to forego the useof lid hygiene products during the study
- Have used systemic antihistamines within 30 days of Day 1
- Have used artificial eyelashes, eyelash extensions, or had other cosmetic eyelash oreyelid procedures within 7 days of Day 1 or be unwilling to forego their use duringthe study
- Contact lens wear within 7 days of Day 1 or unwilling to forego contact lens wear forthe duration of the study
- Be pregnant or lactating at Day 1
Study Design
Total Participants: 36
Treatment Group(s): 2
Primary Treatment: Vehicle of TP-03
Phase: 2
Study Start date:
August 01, 2023
Estimated Completion Date:
June 15, 2024
Study Description
Connect with a study center
Shultz Chang Vision
Northridge, California 91325
United StatesSite Not Available
Vita Eye Clinic
Shelby, North Carolina 28150
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.